#Switzerland #Biopharmaceutical #Basel #mAbxience #Genedata

mAbxience Chooses Genedata Bioprocess to Enhance CDMO Workflows

In an exciting development for the biopharmaceutical sector, mAbxience has announced its partnership with Genedata to implement the Genedata Bioprocess platform. This cutting-edge digital solution is aimed at enhancing the efficiency of bioprocess workflows within mAbxience, a global leader in Contract Development and Manufacturing Organization (CDMO) specializing in biosimilars. This strategic partnership marks a significant commitment by mAbxience to optimize its operations and meet the increasing demands of the global market for high-quality biologics.

Driving Forces Behind the Partnership

As the demand for biosimilars continues to grow, mAbxience faces the challenge of managing complex bioprocess developments. The company recognized the necessity for an integrated platform that could consolidate and harmonize its bioprocess development data. Dr. Ivan Sánchez de Melo, RD Director at mAbxience, emphasized the company's need for a single solution to connect and analyze various data across all stages of development, including upstream processes, downstream processes, and analytical development.

The implementation of Genedata Bioprocess will provide mAbxience with a robust software-as-a-service (SaaS) solution that creates a comprehensive digital backbone for tracking and automating end-to-end workflows in bioprocess development. This integration is expected to facilitate quicker decision-making, enhance collaboration among teams, and improve reproducibility and documentation of processes, all of which are critical for maintaining high standards in biopharmaceutical manufacturing.

Benefits of Genedata Bioprocess Implementation

Utilizing Genedata Bioprocess, mAbxience will benefit from the consolidation of its experimental and process data. By operating within the Genedata Cloud, the company can ensure full data integrity and traceability across its multiple teams, which is essential for maintaining compliance with regulatory standards. This foundational system allows for efficient scaling and prepares mAbxience for the next phase of process modeling – a crucial step as the company navigates the rapidly changing landscape of biologics.

Moreover, positioning itself strategically into the realm of artificial intelligence-driven process optimization, mAbxience is not just enhancing efficiency; it's also making strides toward future innovation in drug manufacturing. The ability to automate various processes means that the company can focus more on innovation and less on routine data management tasks, thereby increasing productivity across the board.

Industry Response and Future Outlook

Othmar Pfannes, President of Genedata, expressed enthusiasm over this collaboration. He noted that bringing mAbxience into the Genedata community expands their footprint in the CDMO sector significantly. Pfannes underscored how centralizing all data into one platform is a major leap towards achieving full automation and ensuring data integrity. Such investments are critical for meeting the demands of a rapidly evolving market.

As the CDMO industry continues to grow, mAbxience’s decision to adopt the Genedata Bioprocess platform showcases its commitment to not only meet current demands but also to innovate for the future. This move sets a benchmark in the industry, demonstrating how the integration of advanced technologies can streamline processes and ensure the delivery of high-quality biologics in a compliant and efficient manner.

Conclusion

With mAbxience selecting Genedata as its software partner, the future of biopharmaceutical manufacturing looks promising. This partnership is indicative of a broader trend within the industry towards embracing digital transformation and automation. As stakeholders keenly observe how this collaboration unfolds, mAbxience stands at the forefront, ready to leverage technology to navigate the complexities of bioprocess development and respond to the growing global demands for biosimilars. The integration of Genedata Bioprocess could very well redefine standards for operational excellence in the biopharmaceutical sector.